Literature DB >> 34266694

Chordoma: Current status, problems, and future directions.

Mary Frances Wedekind1, Brigitte C Widemann2, Gregory Cote3.   

Abstract

Chordoma is a rare tumor that occurs along the axial spine in pediatrics and adults, with an incidence of approximately 350 cases per year in the United States. While typically described as slow-growing, many patients will eventually develop loco-regional relapse or metastatic disease with few treatment options. Despite numerous efforts over the last 10+ years, effective treatments for patients are lacking. As subtypes of chordoma are identified and described in more detail, further knowledge regarding the natural history of each type, tumor location, age differences, genomic variability, and an overall better understanding of chordoma may be the key to developing meaningful clinical trials and effective therapies for patients with chordoma.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Chordoma; Conventional chordoma; Dedifferentiated chordoma; Immunotherapy; Poorly differentiated chordoma

Mesh:

Year:  2021        PMID: 34266694     DOI: 10.1016/j.currproblcancer.2021.100771

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN: 0147-0272            Impact factor:   3.187


  2 in total

1.  XIST sponges miR-320d to promote chordoma progression by regulating ARF6.

Authors:  Yonggang Wang; Zhouzhou Tang; Weichun Guo
Journal:  J Bone Oncol       Date:  2022-07-16       Impact factor: 4.491

2.  PTEN is recognized as a prognostic-related biomarker and inhibits proliferation and invasiveness of skull base chordoma cells.

Authors:  Kaibing Tian; Junpeng Ma; Ke Wang; Da Li; Junting Zhang; Liang Wang; Zhen Wu
Journal:  Front Surg       Date:  2022-09-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.